|
Biotechnology And Medicares New Technology Policy: Lessons From Three Case Studies
Patricia Seliger Keenan,
Peter J. Neumann and
Kathryn A. Phillips
Biotechnology has figured prominently in recent Medicare coverage and payment policies. Biotech treatments push policy boundaries for several reasons: They attract strong patient demand; they often treat rare or life-threatening diseases; they may have uncertain evidence of health benefits; and they are often costly. This paper considers case studies of Medicare coverage for off-label uses of biotech cancer drugs and payments for anemia biopharmaceuticals. The cases suggest Medicares ongoing challenge to balance access considerations, the role and strength of evidence, and cost consequences of new treatments.

What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. J. Neumann, M. S. Kamae, and J. A. Palmer
Medicare's National Coverage Decisions For Technologies, 1999-2007
Health Aff.,
November 1, 2008;
27(6):
1620 - 1631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Oberlander
Through the Looking Glass: The Politics of the Medicare Prescription Drug, Improvement, and Modernization Act
Journal of Health Politics Policy and Law,
April 1, 2007;
32(2):
187 - 219.
[Abstract]
[PDF]
|
 |
|
|